Timothy L. Enns
Profile
Mr. Timothy L.
Enns is Chief Officer-Investor & Media Relations at KineMed, Inc. and Senior VP-Corporate Communications & Marketing at Astex Therapeutics Ltd.
Mr. Enns was previously employed as Senior VP-Communications & Marketing by Astex Pharmaceuticals, Inc., Senior Director-Marketing & Special Projects by SEQUUS Pharmaceuticals, Inc., Senior Vice President by Ascalon International, Inc., and Senior VP-Communications & Business Development by SuperGen, Inc.
He received his undergraduate degree from the University of California, Davis.
Former positions of Timothy L. Enns
| Companies | Position | End |
|---|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Public Communications Contact | 2011-09-12 |
| KINEMED INC | Investor Relations Contact | - |
Ascalon International, Inc.
 Ascalon International, Inc. BiotechnologyHealth Technology Ascalon International, Inc. develops oncology drugs. The company was founded by Keith Benson on February 24, 2010 and is headquartered in Scottsdale, AZ. | Corporate Officer/Principal | - |
SEQUUS Pharmaceuticals, Inc.
 SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Sales & Marketing | 2013-09-08 |
Astex Therapeutics Ltd.
 Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Investor Relations Contact | - |
Training of Timothy L. Enns
| University of California, Davis | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 6 |
|---|---|
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
Astex Pharmaceuticals, Inc.
 Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Health Technology |
Astex Therapeutics Ltd.
Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
SEQUUS Pharmaceuticals, Inc.
SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Health Technology |
Ascalon International, Inc.
Ascalon International, Inc. BiotechnologyHealth Technology Ascalon International, Inc. develops oncology drugs. The company was founded by Keith Benson on February 24, 2010 and is headquartered in Scottsdale, AZ. | Health Technology |
KineMed, Inc.
 KineMed, Inc. Miscellaneous Commercial ServicesCommercial Services KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA. | Commercial Services |
- Stock Market
- Insiders
- Timothy L. Enns
